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COL1A1Osteogenesis imperfecta (OI) is a group of hereditary disorders characterized by bone fragility and osteope-
nia, with a broad spectrum of clinical severity. The majority of cases are dominantly inherited and due to
mutations in type I collagen genes, whereas recessive forms are less frequent and attributable to mutations
in different genes involved in collagen I post translational modiﬁcations and folding (prolyl-3-hydroxylase
complex, SERPINH1, FKBP10).
We report the case of a patient with an initially mild and then progressively severe form of osteogenesis
imperfecta due to a novel homozygous splicing mutation in FKBP10 (intron 8 c.1399+1G>A), which results
in aberrant mRNA processing and consequent lack of FKBP65 chaperone.
Although this mutation does not affect collagen type I post translational modiﬁcations in dermal ﬁbroblasts,
the histomorphometric pattern of our patient's bone sample showed a mineralization defect possibly due to
the mutation in FKBP10.
© 2011 Elsevier Inc. All rights reserved.Introduction
Osteogenesis imperfecta (OI) is a heterogeneous disorder charac-
terized by evidence of malfunctioning connective tissue [1]. Clinical
severity varies widely and patients suffer various degrees of bone
fragility (from mild osteopenia to progressive skeletal deformities
due to recurrent fractures), short stature (from normal to severely
compromised height), sclerae that vary from blue to white coloration
and dental abnormalities (such as dentinogenesis imperfecta).
Before genetic causes were identiﬁed, Sillence classiﬁed four OI
types based on mode of inheritance and on clinical and radiological
criteria: the mild non-deforming type I, the perinatal lethal type II,
the severely deforming type III and the moderately deforming type
IV. In the 1980s, all of these OI forms were explained by heterozygous
mutations in one of the two genes encoding type I collagen (MIM
120150 and 120160), the major component of bone, tendons and
skin, with both quantitative (milder, COL1A1) and qualitative (mod-
erate to lethal, COL1A1 and COL1A2) defects in the synthesis of theces, Pediatric Clinic, University
ico Antonio Scuro, 10, I-37134
rights reserved.protein [2–4]. Moderate to severe OI cases, without COL1 gene muta-
tions and with recessive or unclear heredity, were observed and clas-
siﬁed later on the basis of distinct clinical and bone histological
features as types V and VI. The former is a presumably dominant
form characterized by dense metaphyses, hypertrophic callus forma-
tions, early calciﬁcation of the interosseous membrane at the forearm
and mesh-like bone lamellation on histological examination; the
latter is characterized by disordered mineralization, with usually
high alkaline phosphatase (ALP) values, an augmented osteoid, ﬁsh-
scale pattern of lamellation and with autosomal recessive heredity
[5]. In recent years, the molecular bases of other recessive forms of
OI have been described, and today it is known that some of these
heterogeneous disorders are caused by defects in genes coding for
proteins involved in proper collagen I post-translational modiﬁcation
and folding and in the regulation of osteoblast differentiation [6–11].
Mutations in CRTAP-LEPRE1-PPIB genes, encoding the prolyl-3-
hydroxylation complex, which is responsible for α1(I) Pro986 residue
hydroxylation, affect post-translational modiﬁcation and folding with
a typical lack (or reduction) of 3HyP and extensive lysyl hydroxyl-
ation and glycosylation of pro α chains in the ER, presumably because
of delayed folding of trimers. Null mutations in CRTAP (MIM 605497)
and LEPRE1 (MIM 610339) have been reported to cause severe to
lethal forms of OI with typical rhizomelia [12–17], while mutations
in PPIB (MIM 123841) have more variable clinical and biochemical
outcomes, resulting in moderate to severe cases without rhizomelia,
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gen helix modiﬁcation [18,19]. Recently, new mutations have been
found in the genes coding for the chaperones involved in the intracel-
lular folding and trafﬁcking of collagen triple helix. A SERPINH1/
HSP47 (MIM 600943) homozygous missense mutation has been
described as causing a severely deforming type of OI that is similar
in severity to type III [20]; while mutations in the FKBP10 gene
(MIM 607063), which encodes FKBP65, an ER FK506-binding protein
with peptidyl-prolyl cis–trans isomerase activity (PPIase) and chap-
erone function, have been found in patients whose bone biopsies
showed thin lamellae and a pattern resembling ﬁsh scales [21].
We describe herein the case of a patient who had an initially mild
and then progressively severe form of OI, in spite of the pharmacolog-
ical and physiotherapy treatments [22–24], histologically showing
possible mineralization defects due to an autosomal recessive muta-
tion in FKBP10, not yet described in the literature.
Case report
The index case (O_137, internal code) is the second child born
to healthy (Target height +1 SD), consanguineous Italian parents
(See Appendix for the family pedigree). Family history was non-
contributory and prenatal history was uneventful. The boy was bornFig 1. a. X-ray at birth of lower limbs showing substantially normal long bones. b: X-ray at 1
showing vertebrae plana and deformation; e: trunk and pelvis X-ray at 11 months in AP sho
showing slight reduction of cortical thickness at 11 months. h-i-l: extremely thin lower limat term by induced labor; he weighed 3400 g (40th percentile) at
birth and was 50 cm (40th percentile) in length. At birth he
responded well, although a displaced fracture of the clavicle with
bilateral stretch of brachial plexus was reported. At 8 months of age
the ﬁrst pathological fractures were detected (right tibia greenstick
fracture and pathological rib fractures). A mild motor development
delay was suspected, so at 10 months bone and muscular biopsies
were done which excluded histiocytosis X and a myopathy (data
not available).
Subsequently, fractures after mild trauma became more frequent
(6 fractures between 2 and 5 years of age). A physical examination
at 4 years showed a phenotype resembling OI type I: the boy was
short and thin (98 cm and 15.5 kg: both −1 SD) with white sclera,
long ﬁngers and toes, moderate small joint laxity but no arthrogrypo-
sis, dentinogenesis imperfecta or phenotypic anomalies. Biological
data showed mild sideropenic anemia and bone-related enzymes
within normal ranges, but with the exception of the C-terminal
cross-linked telopeptide of type I collagen (CTX) that was extremely
high. Radiologically we observed the presence of wormian bones in
the skull (Fig. 1b), a progressive cortical width reduction in the long
bones (Figs. 1a-g-h-i-l) and a ﬂattening of a vertebral body with
progressive scoliosis (Figs. 1c-d-e-f). At age 4.5 years, we started the
child on biphosphonate (BP) therapy (Neridronate every 3 months1 months of wormian bones at skull LL; c and d: X-ray at 11 months of trunk AP and LL,
wing coxa valga; f: progressively severe scoliosis at 11.5 years old; g: lower limb X-ray
bs at 11.5 years old.
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(25-OHD) and iron supplements. Because of a concomitant low re-
sponse to growth hormone (GH) stimulation tests (See Appendix),
the boy has been undergoing GH treatment since the age of
7.5 years (113 cm and 23 kg,−2 SD and M, respectively). BP was ad-
ministered continuously until the boy was 10 years old, when they
were suspended for almost 1 year because of surgery; subsequently,
he restarted therapy at half the standard dose (1 mg/kg) every
4 months for 1 year, when the dosage was increased to the standard
dose. There were fewer fractures after 5 years of age (only 1 between
6 and 10 years). Physical check-ups remained non-contributory up to
8 years of age when the initially mild form turned to a moderately
severe phenotype. The boy presented with short stature (117 cm
and 29 kg, respectively −1/−2 SD and +1 SD), a short trunk due
to gradually worsening kyphoscoliosis, with ﬂattening and wedging
of the vertebrae (Fig. 1f) that required a bivalve brace, and eventually
genu valgum with normal extensibility of the joints. No hearing loss
has been veriﬁed, but the patient developed mild prognatism and
myopia. He started using a wheelchair by late childhood, but at
home he is able to walk with assistance. The fracture rate increased
following the suspension of therapy (5 between 11 and 12 years),
but has since subsided. Now, at 13 years old, he is −1/−2 SD for
height and +1/+2 SD for weight (140 cm and 47 kg, respectively)
and surgery for spine stabilization has been scheduled.
Regarding biological data, ALP, as well as parathormone (PTH),
25OHD and calcium urinary secretion have remained within normal
ranges, whereas CTX has always been above normal ranges. Radio-
graphic assessment revealed that osteopenia was severe; subsequently,
this parameter was followed by a six-month dual-energy X-ray absorp-
tiometry (DXA) (See Appendix). A slight but steady increase in bone
mineral density (aBMD) was observed during the ﬁrst three years
of BP therapy. Then progress slowed until GH was started, when we
noticed a slight reactivation of the increase in aBMD, although, and
more important, it seemed to stabilize the aBMD. In fact, when BP and
GH were suspended because of surgery, the aBMD decreased even if
there was no change in height velocity.
Methods
DNA extraction and quantiﬁcation
Proband's genomic DNA (gDNA) was isolated from 400 μl of a
peripheral whole-blood sample using a magnetic particle-based
methodology via an automated puriﬁcation procedure according to
the manufacturer's instructions (Maxwell® 16 DNA Puriﬁcation Kits,
Promega Corporation; Madison, WI, USA). Accurate quantiﬁcation of
obtained gDNA was done by ﬂuorimetric method (Qubit ﬂuorometer,
Invitrogen; Carlsbad, NM, USA).
PCR ampliﬁcation
Coding regions and relative intronic bounderies of the FKBP10
gene were ampliﬁed by 10 speciﬁc intronic couples of primers (See
Appendix) and each PCR reaction occurred in 25 μl ﬁnal volume
with 20 ng of gDNA, 400 nM of each primer, 200 μM of each dNTP
(Invitrogen; Carlsbad, NM, USA), 1.5 mM MgCl2, 5× Colorless Go
Taq® Flexi Buffer and 1 U of Go Taq® Hot Start Polymerase (Promega
Corporation; Madison, WI, USA). Following an initial 2-min denatur-
ation step at 95 °C, 35 cycles were repeated consisting of 30 s at
95 °C, 30 s at each amplicon speciﬁc annealing temperature (range
62 °C–66 °C) and 30 s at 72 °C followed by a ﬁnal extension time of
5 min at 72 °C. Ampliﬁcation was performed on a gradient thermal
cycler (Mastercycler epgradient, Eppendorf; Hamburg, Germany)
and PCR product was checked for speciﬁcity and for quantiﬁcation
by electrophoretic migration on 2% agarose gel.PCR product puriﬁcation and sequence analysis
Ampliﬁed fragments were puriﬁed by a selective DNA/silica
membrane binding reaction carried out on a column support (Illustra
GFX PCR DNA and gel band puriﬁcation kit, GE Healthcare; Bucking-
hamshire, UK); and 50 fmol of the same PCR product was used for
the dye terminator cycle sequencing reaction with the CEQ DTCS
Quick Start Kit (Beckman Coulter; Fullerton, CA, USA) according to
the manufacturer's protocol. The sequencing reaction product was
puriﬁed by ethanol precipitation, resuspended in a sample loading
solution and analyzed with a capillary electrophoresis sequencer
(CEQ 8800, Beckman Coulter; Fullerton, CA, USA).qRT-PCR ampliﬁcation
The expression of FKBP10 and COL1A1 in ﬁbroblasts, which share
a mesodermal origin with osteoblasts, was examined by means of
a real-time reverse transcriptase polymerase chain reaction (qRT-
PCR) and normalized to GAPDH and HPRT1 mRNA levels. Speciﬁcally,
500 ng of total extracted RNA were retrotrascripted with iScript cDNA
Synthesis Kit and then 10 ng ampliﬁed with IQ SYBR Green Supermix
on a IQ5 thermocycler (Bio-Rad Laboratories; Hercules, CA, USA).
After an initial 3-min denaturation step at 95 °C, 40 cycles were
repeated consisting of 10 s at 95 °C and 30 s at 60 °C.Cell cultures
Dermal ﬁbroblast cultures were established from explanted skin
biopsies taken from the patient and from a normal individual (con-
trol) with appropriate consent and grown in high glucose DMEM
(Euroclone, Italy) supplemented with 10% FBS, 2 mM L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin. For each experi-
ment, 250,000 cells were seeded into 35-mm dishes and left to
grow for 1 day. Eighty percent conﬂuent ﬁbroblasts were then incu-
bated for 24 h with DMEM supplemented with 1% FBS, 100 μg/ml
ascorbic acid, L-glutamine, penicillin and streptomycin. Media and
cell layers were collected from the dishes in the presence of protease
inhibitors (Roche, Germany) on ice.In vitro biochemical studies
Type I collagen secreted by patient and control ﬁbroblasts were
isolated as detailed elsewhere [25]. Ammonium sulfate precipitates
of media and cell layer procollagens were digested with pepsin,
ﬂuorescently labeled with Cy5, denatured at 60 °C for 10 min and
separated by SDS-PAGE on 0.5% urea gels (6% running, 4% stacking).
Separated collagens were scanned with a Typhoon laser scanner
and analyzed with ImageQuant 5.1 (GE Healthcare; Buckinghamshire,
UK).Western blot FKBP65
Control and patient cells were lysated in RIPA buffer supplemen-
ted with protease inhibitor cocktail (Roche, Germany), separated by
SDS-PAGE on a 10% gel under reducing conditions and transferred
to a pvdf membrane. Western blots were probed with two alternative
clones of a monoclonal antibody against human-FKBP65 (M02-3B5
and M13 2D4, Abnova, Taiwan) and with an anti-α-tubulin antibody
(Calbiochem, San Diego, CA, USA) as loading control. Reactive bands
were revealed by chemiluminescence with secondary antibody con-
jugated with horseradish peroxidise (R&D Systems, Minneapolis,
MN, USA).
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An iliac crest biopsy was taken at 13 years, at 6 months after sus-
pension of 7 years of neridronate treatment, transiliac bone biopsy,
taken from the iliac crest, was ﬁxed in 70% ethanol and embedded
undecalciﬁed in methyl-methacrylate resin (Merck 800590, Germany).
Bone sections were cut with a microtome (Polycut S, Leica Microsys-
tems, Wetzlar, Germany) equipped with a carbide-tungsten blade,
stained with Goldner's stain and toluidine blue and mounted onmicro-
scope slides for histomorphometricmeasurements. Some sectionswere
left unstained for themeasurement of ﬂuorescent labeling. The sections
were obtained from three different levels of the methyl-methacrylate
block, each separated by a thickness of 250 μm. Histomorphometric
results were calculated as the mean of the values obtained from the
three different levels as an approximation of a 3-D evaluation. This
also avoided replicating the sampling of any single bone remodeling
unit.
Measurements were taken by means of an image analysis system
consisting of an epiﬂuorescent microscope (Leica DM2500) con-
nected to a digital camera (Leica DFC420 C) and a computer equipped
with a speciﬁc software for histomorphometric analyses (Bone 3.5,
Explora Nova, France). Histomorphometric parameters were reported
in accordance with the ASBMR Committee nomenclature [26].
Results
Identiﬁcation of the mutation and FKBP10 expression
Complete sequencing of the COL1A1, COL1A2, CRTAP, LEPRE1 and
SERPINH1 genes revealed the absence of any pathological nucleotidic
variation.
The proband harbors a homozygous c.1399+1G>A mutation in
the ﬁrst of two strictly conserved nucleotides in the donor splice
site of intron 8 inherited in a recessive manner from the healthy het-
erozygous parents (Fig. 3a). This variation results in the production of
two different steady mRNA molecules as is shown by RT-PCR ampliﬁ-
cation (Fig. 3e): a ﬁrst molecule (Fig. 3b) with complete skipping of
exon 8, in which a shift in the reading frame generates a premature
stop codon in exon 9 (p.His420ProfsX12); and a second longer mole-
cule (Fig. 3c), where recognition of a cryptic donor site at position
c.1303 causes the incorporation of a small fragment of exon 8 (ﬁrst
46 bp) with a consequent shift in the reading frame and the introduc-
tion of a premature stop codon in exon 10 (p.Val435ProfsX64).
Gene expression analysis by real-time RT-PCR showed a reduced
level of FKBP10 in the patient's ﬁbroblasts compared to wild-type
(0.465 fold, Fig. 3f), that could be explained by other different unsta-
ble splicing products, harboring a premature termination codon or by
down-regulation of the same gene. Western blot analysis showed
that protein product FKBP65 was undetectable in patient cells.
Collagen expression
COL1A1 expression, evaluated by qRT-PCR, revealed an increase
in mRNA levels (2.188 fold; Fig. 3f), as if there was a compensative
up-regulation of the collagen production in response to its delayed
secretion [21]. On the other hand, gel electrophoresis of proband col-
lagen I showed normal α1(I) and α2(I) amounts in media compared
with healthy control cells. No evidence of alterations in electropho-
retic chain migration (Figs. 2d–e) indicates that the FKBP10 mutation
does not affect post translational modiﬁcation in collagen type I.
Histological ﬁndings
Comparing the histomorphometric pattern of the patient's sample
with those previously described [5,27], there is a poor, diffuse uptake
of the tetracycline, under ﬂuorescent light (Fig. 2b). Adjustedapposition rate, trabecular and osteoid thickness could be similar to
type VI OI (Table 1); on the other hand, osteoid surface is more like
normal controls and qualitative evaluation under polarized light
showed a loss of the normal orientation of the lamellae with a osteo-
malacic pattern, conﬁrmed by the mineralization lag time, that is here
even longer than the full range for type VI OI. (Figs. 2a–c).
Discussion
We describe a patient with progressive OI, initially similar to a
mild form and gradually evolving towards a moderately severe
form, worsening both in terms of growth rate and number of frac-
tures. The patient turned out to be affected by autosomal recessive
OI due to a homozygous mutation in FKBP10. He is the only affected
member in all of his extended family.
Interestingly, the OI phenotype previously described in associa-
tion with FKBP10 mutations seems more severe [21] than the one
we describe here. Since none of the patients described in early
works is reported to be taking BP, we believe that BP together with
GH therapy in this case helped obtain steady state metabolism and
better bone mass than would have occurred in the natural course of
the disease, as it is shown in some OI types [28]. We think anomalies
in FKBP10 expression could be compared to other chaperone defects,
causing recessive OI. Similarly to cases where CyPB is absent and the
OI phenotype is less severe compared to deﬁciencies of P3H1 or
CRTAP, a lack of FKBP65 could cause milder forms of OI than those
due to HSP47 insufﬁciency [20]. Moreover, the possible mineraliza-
tion defects we showed at the histomorphometry and the absence
of limb pterygia, could conﬁrm that FKBP10 mutations can cause a
form of OI not necessarily with arthrogryposis [29,30].
Concerning biological data, we do not report any alteration in
the majority of bone metabolic markers ALP, PTH, 25OHD or calcium
(except for CTX that has always remained above normal ranges, as it
usually does in many OI patients). As far as the radiological aspects
are concerned, our patients showed mild vertebral ﬂattening, severe
scoliosis and wormian bones in the skull, a feature otherwise present
in the majority of the other FKBP10 mutated patients [29]. Evaluating
the bone histology, we have to consider that the patient had been
treated for 7 years with BP and that there is no published evidence
that remodeling activity is restored to pre-treatment levels after stop-
ping neridronate for 6 months; the mineralization defect we noticed
if not due to direct BP effect on bone remodeling could be part of
our patient condition. A constant increase in BMD, even if slighter
than in OI types I, III and IV, was observed during the ﬁrst 3 years of
treatment with BP. GH treatment was helpful in bringing about a
slight reactivation of the increasing BMD, but overall it seemed to
stabilize the BMD. In fact, when it was suspended because of surgical
intervention, BMD decreased, even though there was no change in
the speed of growth. At any rate, BP treatment in our patient im-
proved bone mineral mass and reduced fracture incidence, but with
minor effects if compared with other types of OI under treatment
[31]. Comparing our patient with the other known OI, he differs
from both type III, by the relative wellbeing in the ﬁrst years of life,
and mild OI forms by the following clinical history and ﬁnal bone
deformations. The progressive moderate severity of his clinical evolu-
tion, the possible mineralization defect and the osteoporosis degree
could resemble those of type VI. However, our patient ALP values
are within the normal range and the other histomorphometric ﬁnd-
ings are not typical for OI type VI [5,31]. Lastly both the clinical histo-
ry and the osteoporosis are less severe compared to other recessive OI
forms, although extremely short stature (typical of types VII and VIII)
also contributes to a very low z score on DXA (DXA z scores of −5.5
vs. average DXA z scores of −6 to −7 in types VII and VIII).
Procollagen I is a heterotrimer assembled in the lumen of the ER;
chaperones such as PDI, BiP, GRP94, HSP47 and FKBP65 prevent pre-
mature association between procollagen chains and assist proper
Fig 2. a–c. Histological sections from iliac crest of the affected individual showing a signiﬁcant increase in both osteoid thickness and surface (a), revealing poor, diffuse uptake of
the tetracycline labels under ﬂuorescent light (b) and abnormal lamellar bone patterns under polarized light (c); d. Pepsin-digested type I collagen in the medium and cell layer of
cultured dermal ﬁbroblasts from O_137 and control. Migration of α1 and α2 chains is normal compared to a standard collagen type I protein. Relative amounts of secreted α1 and
α2 chains in patient and control are identical; e. Western blot of FKBP65 and α-tubulin (as loading control) in patient and control ﬁbroblasts. Two monoclonal antibodies (M02 3B5
and M13 2D4 clones — AbNova®) were used which gave analogous results. The image is representative of the two.
347G. Venturi et al. / Bone 50 (2012) 343–349registration, folding into the collagen triple helix and subsequent
trafﬁcking [32,33].
To date, a small number of mutations in SERPINH1 [20] and FKBP10
[21,29] have been associated with moderate to lethal phenotypes,
showing the important role of ER-resident chaperones in collagen
biosynthesis and their effective involvement in the clinical manifesta-
tions of non-classic OI.
The splicing mutation found in our patient causes the production
of two stable mRNA molecules whose translation could result in





age 13 yrs [26]
Bone volume/tissue volume (%) 18.9 24.4±4.3
Trabecular thickness (μm) 82 148±23
Osteoid thickness (μm) 12.32 6.7±1.7
Osteoid surface/bone surface (%) 28 22.1±7.8
Osteoid volume/bone volume (%) 14 2.12±1.00
Mineral apposition rate (μm/day) 0.41 0.87±0.09
Bone formation rate (μm3/μm2/day) 0.03 0.037±0.02
Activation frequency (#/year) 0.32 0.83±0.35
Adjusted apposition rate (μm/day) 0.10 0.46±0.10
Mineralization lag time (days) 122 14.5±3.0
Erosion surface/bone surface (%) 16 14.9±5.6
Osteoclast surface/bone surface (%) 2.4 0.94±0.38
All thickness/depth results are corrected for obliquity of sections by multiplying by π/4.terminal 4 amino acids HEEL that represent the signal peptide for
ER retention (Fig. 3d). Western blot analysis did not reveal any
FKBP65 signal in the patient ﬁbroblasts. Considering that the new
termination codons fall in the ﬁnal exons, it is plausible that both sta-
ble transcripts could by-pass the nuclear nonsense-mediated-decay
mechanism (NMD) and the corresponding defective proteins were
degraded.
As previously reported [21], the lack of FKBP65 leads to an accu-
mulation of type I procollagen within the cells and to a delay in its
secretion without evident changes of post-translational modiﬁcations
towards collagenous molecules. In agreement with Alanay et al., elec-
trophoresis of our patient type I procollagen (data not shown) and
collagen (Fig. 2d) showed a normal pattern.
It has been proven that FKBP65 acts as a chaperone on collagen
with effects comparable to HSP47, both of which prevent premature
association of procollagen into triple helix and increasing its thermal
stability [32]. At any rate, it is probable that a lack of FKBP65 function
causes ﬂaws in the correct synthesis of collagen and other ECM pro-
teins (such as tropoelastin) at folding level and during their secretion
into the extracellular matrix. In fact, in a manner similar to HSP47 null
cells, the lack of FKBP65 has been shown to lead to a delay in procol-
lagen I secretion and to the presence of its intracellular aggregates
[21]. A defect in collagen ﬁbrillogenesis has also been detected in
these cells, giving rise to ﬁbrils that are branched and thinner than
normal [33].
Further studies on FKBP65 mutant cells are needed in order to
highlight potential ﬁbrillogenesis aberrations that could cause anom-
alous orientation of the lamellae at bone hystomorphology levels.
Fig 3. a. Patient's sequence of gDNA around the site of homozygous mutation IVS8+1G>A; the two vertical lines deﬁne base c.1399+1 (NM_021939.3) in the ﬁrst strictly conserved
position of the donor splicing site in intron 8. b. Patient's cDNA showing the sequence of transcript 1 with complete skipping of exon 8; vertical line deﬁnes last nucleotide of exon 7
from ﬁrst nucleotide of exon 9. c. Sequence of exon 8 included in the mRNA of transcript 2 as a consequence of the activation of a cryptic donor splice site. Both transcripts 1 and 2
generate frameshift in the reading frame with the introduction of premature stop codons. d. Cartoon of the FKBP65 molecule and of two predicted proteins generated by the
mutation. FKBP-type peptidyl-prolyl cis–trans isomerase; EF/Hand domain, calcium binding motif; ER-retention sequence. e. RT-PCR of FKBP10 cDNA from control and O_137 show-
ing the presence of two bands of 340 and 386 bp (483 bp wild type length) corresponding to two different transcripts; the third higher band (*) is an in vitro created heteroduplex
between transcript 1 and 2 as demonstrated by its disappearance during 75 °C chromatographic separation in a DHPLC instrument (data not shown). f. qRT-PCR with relative ex-
pression levels of COL1A1 and FKBP10 mRNA in cultured ﬁbroblasts normalized to GAPDH and HPRT1 used in combination as housekeeping genes. The experiments were repeated
independently three times.
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